Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Short Interest Update

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the target of a large growth in short interest in May. As of May 29th, there was short interest totaling 31,099 shares, a growth of 360.2% from the May 14th total of 6,757 shares. Currently, 3.0% of the company’s stock are sold short. Based on an average daily volume of 125,406 shares, the days-to-cover ratio is currently 0.2 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Bluejay Diagnostics Trading Up 0.2%

BJDX traded up $0.01 during trading on Thursday, hitting $4.50. The stock had a trading volume of 27,953 shares, compared to its average volume of 854,678. The firm has a market cap of $4.64 million, a PE ratio of -0.39 and a beta of 0.82. Bluejay Diagnostics has a 12 month low of $1.62 and a 12 month high of $16.68. The company has a 50 day simple moving average of $2.30 and a 200-day simple moving average of $2.76.

Bluejay Diagnostics (NASDAQ:BJDX) last announced its earnings results on Thursday, May 7th. The company reported ($1.95) EPS for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC acquired a new position in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned 9.15% of Bluejay Diagnostics as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 18.47% of the company’s stock.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.